In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

Alpha-gal syndrome (AGS) is a severe tick-vectored food allergy caused by sensitivity to the galactose-alpha-1,3-galactose ...

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...

The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

Tiffany Renee Thomas is an experienced employment law attorney and HR professional whose career serves as an example of both ...

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...